These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2897304)

  • 21. [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
    Cheymol G
    Bull Acad Natl Med; 1990 Oct; 174(7):959-67; discussion 967-8. PubMed ID: 1981983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of beta-adrenoceptor blocking properties of sotalol, oxprenolol, propranolol and pindolol on rabbit intestinal smooth muscle.
    Salimi M
    Pharmacology; 1975; 13(5):441-7. PubMed ID: 1802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
    Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
    Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side-effects of beta-adrenoceptor blocking drugs assessed by visual analogue scales.
    Lewis RV; Jackson PR; Ramsay LE
    Br J Clin Pharmacol; 1985 Feb; 19(2):255-7. PubMed ID: 2859044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
    Antonaccio MJ; High J; DeForrest JM; Sybertz E
    J Pharmacol Exp Ther; 1986 Jul; 238(1):378-87. PubMed ID: 2873238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.
    Frishman WH; Lazar EJ; Gorodokin G
    Clin Pharmacokinet; 1991 Apr; 20(4):311-8. PubMed ID: 1674683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview.
    Maideen NMP; Rajkapoor B; Muthusamy S; Ramanathan S; Thangadurai SA; Sughir AA
    Curr Drug Metab; 2021; 22(9):672-682. PubMed ID: 34182907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iatrogenic dermatoses caused by beta-blocking drugs].
    Alinovi A; Branchetti A; Barella PA
    G Ital Dermatol Venereol; 1983; 118(6):341-8. PubMed ID: 6143722
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect.
    Gugler R; Bodem G; Dengler HJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():473s-475s. PubMed ID: 15758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interactions of beta-adrenoceptor blockers.
    Brodde OE; Kroemer HK
    Arzneimittelforschung; 2003; 53(12):814-22. PubMed ID: 14732961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy.
    Yamada Y; Shibuya F; Hamada J; Sawada Y; Iga T
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):131-45. PubMed ID: 8719233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-adrenoceptor-blocking drugs in the elderly.
    Tregaskis BF; McDevitt DG
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S25-8. PubMed ID: 11527132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes.
    Robbiano L; Martelli A; Allavena A; Mazzei M; Gazzaniga GM; Brambilla G
    Cancer Res; 1991 May; 51(9):2273-9. PubMed ID: 1673086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-adrenergic antagonist inhibition of hepatic 3,5,3'-triiodothyronine production.
    Shulkin BL; Peele ME; Utiger RD
    Endocrinology; 1984 Sep; 115(3):858-61. PubMed ID: 6146516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisoprolol: a new beta-adrenoceptor blocking drug.
    Prichard BN
    Eur Heart J; 1987 Dec; 8 Suppl M():121-9. PubMed ID: 2897295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blockers and central nervous system side effects.
    McAinsh J; Cruickshank JM
    Pharmacol Ther; 1990; 46(2):163-97. PubMed ID: 1969642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
    Lancaster SG; Sorkin EM
    Drugs; 1988 Sep; 36(3):256-85. PubMed ID: 2903820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
    Wellstein A; Palm D; Belz GG; Butzer R; Polsak R; Pett B
    Eur Heart J; 1987 Dec; 8 Suppl M():3-8. PubMed ID: 2897299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.